Ipca Labs
The pharma firm has signed a global licensing pact with Bhami Research Lab (BRL) to develop monocolonal antibody therapies for oncology and inflammatory diseases.
BRL has the proof of concept (POC) development and formulation development, while further research and development, clinical trials, commercial manufacturing and launch are by the Ipca licensing fee.
BRL will receive the defined milestone fee pertaining to the technology transfer royalty. It will also receive royalty on net sales upon commercialisation of the product.
The stock ended the previous session 1.5% lower at ₹1,589 apiece. It has risen 13.7% this year, so far.
Aurobindo Pharma
The US Food and Drug Administration (USFDA) has issued 11 observations for the company’s Eugia Unit III in Telangana and classified it as official action indicated (OAI). It is a formulations manufacturing facility.
The US drug regulator inspected the unit from January 27 to February 6, following which it issued the 11 observations.
An Official Action Indicated (OAI) classification means that significant regulatory violations were found at a facility and the agency is recommending a formal administrative or regulatory action.
The stock ended the previous session 0.3% up at ₹1,468 apiece. It has gained 23% this year, so far.
Dr Reddy’s Laboratories
The company has announced the first-to-market launch of Bosutinib tablets 400mg, which is the of Bosulif in the United States.
Dr Reddy’s Laboratories was the first to file on the oncology drug. Its market size is $253.8 million in the 12 months ending April 2026.
The stock ended the previous session 0.2% lower at ₹1,272.9 apiece. It has declined 4.8% in the past month and is up 1.6% this year, so far.
Also Read: Vedanta’s four demerged entities set to list today: All you need to know
Krishna Institute Of Medical Sciences (KIMS)
The company has announced that it will be raising ₹600 crore via the issue of warrants to its promoters.
As part of the fund raise, the board will issue 77.02 lakh warrants to promoter group at ₹779 per warrant. These warrants will fully convert into equity shares within 18 months.
KIMS will also convene an Extraordinary General Meeting (EGM) on July 9 to seek shareholder approval for this proposed fund raise.
Shares of KIMS ended 2.3% higher on Friday at ₹783. The stock is up 27% so far this year.
